Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar

This article was originally published in The Pink Sheet Daily

Executive Summary

Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.

You may also be interested in...



“Use With Caution” Isn’t Specific Enough For Labeling, FDA Tells Merck At Vorapaxar Panel

Advisory committee struggles to give a labeling recommendation for lightweight patients, who saw lower efficacy using the platelet inhibitor.

FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes

As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel